

RIGEL PHARMACEUTICALS INC

Form 8-K

July 09, 2009

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D. C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **July 9, 2009**

**RIGEL PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation)

**0-29889**  
(Commission File No.)

**94-3248524**  
(IRS Employer Identification No.)

**1180 Veterans Boulevard**

Edgar Filing: RIGEL PHARMACEUTICALS INC - Form 8-K

South San Francisco, CA 94080

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: **(650) 624-1100**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**ITEM 8.01. OTHER EVENTS.**

On July 9, 2009, Rigel Pharmaceuticals, Inc. issued a press release announcing results of its TASKi2 Phase 2b clinical trial of R788 (fostamatinib disodium). The press release, dated July 9, 2009, entitled Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

**ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.**

**(d) Exhibits.**

Exhibit No.	Description
99.1	Press Release, dated July 9, 2009, entitled Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial .

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

RIGEL PHARMACEUTICALS, INC.

Dated: July 9, 2009

By: */s/ Dolly A. Vance*  
*Dolly A. Vance*  
*Senior Vice President, General Counsel and*  
*Corporate Secretary*

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release, dated July 9, 2009, entitled Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial .